Status and phase
Conditions
Treatments
About
Primary Objective:
To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.
Secondary Objectives:
Full description
The total study duration for participants is planned to be approximately 9 months. The study will consist of a screening visit, a baseline period (4 weeks), a 12-week double-blind treatment period, a 12-week open-label treatment period, and a follow-up period lasting approximately 3 months after the last dose of treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
365 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Teva U.S. Medical Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal